Thetis Pharmaceuticals Presents Clinical Data at IBD Innovate Conference in NYC

Phase 1a Clinical Results Demonstrate a Favorable Safety Profile and
BLT1 Target Engagement In Healthy Volunteers

ESSEX, Conn.--—April 9, 2025—Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, today announced the presentation of clinical data at the 2025 IBD Innovate Conference of Crohn’s and Colitis Foundation in New York City, April 9-10, 2025.

“These data support TP-317’s unique potential as an oral, first-in-class therapy that promotes epithelial repair and immune homeostasis,” said Gary Mathias, CEO of Thetis Pharmaceuticals. “The clinical data confirm safety, predictable pharmacokinetics, and BLT1 engagement in humans. With $9 million of funding from the Helmsley Charitable Trust, we will advance TP-317 into Phase 1b/2a trials in IBD patients commencing in early 2026.”

This Phase 1a clinical trial evaluated the pharmacokinetics, pharmacodynamics, and safety profile of oral TP-317 in healthy volunteers. Key findings include:

• Single ascending doses of TP-317 were well-tolerated, with no treatment-related adverse events.

• TP-317 achieved systemic Resolvin E1 (RvE1) levels well above the EC50 for BLT1 activation, confirming target engagement.

• Transient neutropenia (a known pharmacodynamic effect of RvE1 at BLT1) was observed but quickly rebounded within two hours in all subjects monitored for this effect.

• PK analysis showed dose-proportional increases in RvE1 exposure, supporting a predictable oral dosing profile.

About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Its lead candidate, TP-317, is a first-in-class oral RvE1 drug candidate that targets the LTB4-BLT1 pathway to mobilize the body’s natural ability to resolve disease and restore immune homeostasis. For more information, please visit www.thetispharma.com, and follow us on LinkedIn.

Contact
Tracy Lessor
SVP, Communications
Thetis Pharma
617-519-9827
tracy@tlowcommunications.com